Joseph Schlessinger

List of Publications by Year
in descending order

210	53,243	2215	1900
papers	citations	99 h-index	208 g-index

214	214	214	43587
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design of protein-binding proteins from the target structure alone. Nature, 2022, 605, 551-560.	27.8	164
2	A hypothalamic pathway for Augmentor Î±â€“controlled body weight regulation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200476119.	7.1	8
3	Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies. ACS Medicinal Chemistry Letters, 2022, 13, 819-826.	2.8	6
4	Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands. Journal of Medicinal Chemistry, 2022, 65, 8380-8400.	6.4	7
5	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
6	Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant. Tetrahedron Letters, 2021, 77, 153248.	1.4	7
7	Structural basis for ligand reception by anaplastic lymphoma kinase. Nature, 2021, 600, 148-152.	27.8	21
8	Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature, 2021, 600, 153-157.	27.8	28
9	Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31914-31922.	7.1	9
10	Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core. Journal of Medicinal Chemistry, 2020, 63, 5324-5340.	6.4	17
11	FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with Î±-Klotho. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31800-31807.	7.1	18
12	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22730-22736.	7.1	52
13	Small molecule combats cancer-causing KRAS protein at last. Nature, 2019, 575, 294-295.	27.8	19
14	Structures of ligand-occupied Î²-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7819-7824.	7.1	27
15	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 619-624.	7.1	49
16	Structures of Î²-klotho reveal a â€˜zip codeâ€™-like mechanism for endocrine FGF signalling. Nature, 2018, 553, 501-505.	27.8	160
17	Reminiscences on the "Classic" 1976 FRAP Article in Biophysical Journal. Biophysical Journal, 2018, 115, 1156-1159.	0.5	3
18	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research, 2018, 24, 4845-4853.	7.0	18

#	Article	IF	Citations
19	Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-Î±). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8340-8345.	7.1	12
20	Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. ACS Medicinal Chemistry Letters, 2017, 8, 618-621.	2.8	38
21	JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules. ACS Medicinal Chemistry Letters, 2017, 8, 614-617.	2.8	26
22	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery, 2017, 7, 1420-1435.	9.4	507
23	Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12027-12032.	7.1	78
24	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelialâ€“mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	7.1	181
25	Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4784-93.	7.1	18
26	Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-Î²â€“dependent mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4558-66.	7.1	40
27	Regression of Chemotherapy-Resistant Polymerase Ïµ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clinical Cancer Research, 2016, 22, 5682-5687.	7.0	145
28	Data publication with the structural biology data grid supports live analysis. Nature Communications, 2016, 7, 10882.	12.8	113
29	Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain. Genes To Cells, 2016, 21, 350-357.	1.2	3
30	Early and multiple origins of metastatic lineages within primary tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2140-2145.	7.1	157
31	The Dark Side of Cell Signaling: Positive Roles for Negative Regulators. Cell, 2016, 164, 1172-1184.	28.9	97
32	Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in <scp>FGFR</scp>1 kinase domain. Genes To Cells, 2015, 20, 860-870.	1.2	7
33	Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Science Signaling, 2015, 8, ra6.	3.6	72
34	Augmentor Î± and Î² (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligandâ€“receptor interactions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15862-15867.	7.1	125
35	Improved survival of patients with hypermutation in uterine serous carcinoma. Gynecologic Oncology Reports, 2015, 12, 3-4.	0.6	14
36	The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. Molecular Cell, 2015, 57, 191-201.	9.7	26

#	Article	IF	Citations
37	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nature Genetics, 2015, 47, 996-1002.	21.4	348
38	Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E493-E502.	3.6	131
39	FGF1 and FGF19 reverse diabetes by suppression of the hypothalamicâ€“pituitaryâ€“adrenal axis. Nature Communications, 2015, 6, 6980.	12.8	106
40	Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13225-13230.	7.1	36
41	Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1772-1777.	7.1	35
42	The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases. Cold Spring Harbor Perspectives in Biology, 2014, 6, a020768-a020768.	5.5	345
43	Receptor Tyrosine Kinases: Legacy of the First Two Decades. Cold Spring Harbor Perspectives in Biology, 2014, 6, a008912-a008912.	5.5	255
44	The docking protein FRS2Î± is a critical regulator of VEGF receptors signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5514-5519.	7.1	20
45	Differential TAM receptorâ€“ligandâ€“phospholipid interactions delimit differential TAM bioactivities. ELife, 2014, 3, .	6.0	214
46	Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17832-17837.	7.1	25
47	Tony Pawson (1952â€“2013). Cell, 2013, 154, 1180-1181.	28.9	0
48	A step towards treating KRAS-mutant NSCLC. Lancet Oncology, The, 2013, 14, 3-5.	10.7	6
49	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2916-2921.	7.1	275
50	RAC1 ^{P29S} is a spontaneously activating cancer-associated GTPase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 912-917.	7.1	146
51	The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. Journal of Cell Biology, 2012, 199, 15-19.	5.2	7
52	Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4419-4424.	7.1	140
53	Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16107-16112.	7.1	73
54	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 2012, 44, 1006-1014.	21.4	1,052

#	Article	IF	Citations
55	Aryl extensions of thienopyrimidinones as fibroblast growth factor receptor 1 kinase inhibitors. Tetrahedron Letters, 2011, 52, 2228-2231.	1.4	11
56	Pyk2 Is Required for Neutrophil Degranulation and Host Defense Responses to Bacterial Infection. Journal of Immunology, 2011, 186, 1656-1665.	0.8	68
57	Discovery of Novel Fibroblast Growth Factor Receptor 1 Kinase Inhibitors by Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2010, 53, 1662-1672.	6.4	60
58	Asymmetric Tyrosine Kinase Arrangements in Activation or Autophosphorylation of Receptor Tyrosine Kinases. Molecules and Cells, 2010, 29, 443-448.	2.6	105
59	FRS2Î± Regulates Erk Levels to Control a Self-Renewal Target Hes1 and Proliferation of FGF-Responsive Neural Stem/Progenitor Cells. Stem Cells, 2010, 28, 1661-1673.	3.2	30
60	Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature, 2010, 464, 783-787.	27.8	478
61	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	27.8	1,610
62	Proline-rich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16234-16239.	7.1	50
63	Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1906-1911.	7.1	89
64	Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2866-2871.	7.1	66
65	Cell Signaling by Receptor Tyrosine Kinases. Cell, 2010, 141, 1117-1134.	28.9	4,613
66	The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations. Science Signaling, 2009, 2, ra6.	3.6	123
67	Surface Binding Inhibitors of the SCFâ€“KIT Proteinâ€“Protein Interaction. ChemBioChem, 2009, 10, 1955-1958.	2.6	18
68	An FGF4-FRS2Î±-Cdx2 Axis in Trophoblast Stem Cells Induces BMP4 to Regulate Proper Growth of Early Mouse Embryos. Stem Cells, 2009, 28, N/A-N/A.	3.2	49
69	The Selectivity of Receptor Tyrosine Kinase Signaling Is Controlled by a Secondary SH2 Domain Binding Site. Cell, 2009, 138, 514-524.	28.9	142
70	Crystal structures of free and ligand-bound focal adhesion targeting domain of Pyk2. Biochemical and Biophysical Research Communications, 2009, 383, 347-352.	2.1	38
71	Spontaneously Formed EGFR Dimers Are Primed For Activation. Biophysical Journal, 2009, 96, 368a.	0.5	0
72	FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. Journal of Clinical Investigation, 2009, 119, 1077-1079.	8.2	32

#	Article	IF	Citations
73	'Tuning' of type I interferonâ€“induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nature Immunology, 2008, 9, 186-193.	14.5	74
74	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.	7.1	1,206
75	Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7681-7686.	7.1	71
76	Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19802-19807.	7.1	35
77	Lacrimo-Auriculo-Dento-Digital Syndrome Is Caused by Reduced Activity of the Fibroblast Growth Factor 10 (FGF10)-FGF Receptor 2 Signaling Pathway. Molecular and Cellular Biology, 2007, 27, 6903-6912.	2.3	64
78	Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3937-3942.	7.1	57
79	Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density inPyk2â^'/â^'mice. Journal of Cell Biology, 2007, 178, 1053-1064.	5.2	208
80	Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor. Cell, 2007, 130, 323-334.	28.9	290
81	Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring. Cell, 2006, 127, 45-48.	28.9	87
82	Autophosphorylation of FGFR1 Kinase Is Mediated by a Sequential and Precisely Ordered Reaction. Molecular Cell, 2006, 21, 711-717.	9.7	203
83	Mutations in different components of FGF signaling in LADD syndrome. Nature Genetics, 2006, 38, 414-417.	21.4	190
84	Receptor Protein Tyrosine Phosphatase Î³ Is a Marker for Pyramidal Cells and Sensory Neurons in the Nervous System and Is Not Necessary for Normal Development. Molecular and Cellular Biology, 2006, 26, 5106-5119.	2.3	40
85	Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9796-9801.	7.1	99
86	On the nature of low- and high-affinity EGF receptors on living cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5735-5740.	7.1	91
87	A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nature Biotechnology, 2005, 23, 201-207.	17.5	220
88	Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface. Molecular and Cellular Biology, 2005, 25, 7734-7742.	2.3	247
89	Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18866-18871.	7.1	100
90	Cellular signaling by fibroblast growth factor receptors. Cytokine and Growth Factor Reviews, 2005, 16, 139-149.	7.2	1,677

#	Article	IF	Citations
91	The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 923-928.	7.1	96
92	A structure-based model for ligand binding and dimerization of EGF receptors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 929-934.	7.1	111
93	Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 935-940.	7.1	168
94	The Docking Protein Gab1 Is an Essential Component of an Indirect Mechanism for Fibroblast Growth Factor Stimulation of the Phosphatidylinositol 3-Kinase/Akt Antiapoptotic Pathway. Molecular and Cellular Biology, 2004, 24, 5657-5666.	2.3	76
95	Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. Structure, 2004, 12, 2233-2247.	3.3	360
96	The biochemical response of the heart to hypertension and exercise. Trends in Biochemical Sciences, 2004, 29, 609-617.	7.5	89
97	The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biology, 2004, 2, 24.	3.8	167
98	A Glutamine Switch Mechanism for Nucleotide Selectivity by Phosphodiesterases. Molecular Cell, 2004, 15, 279-286.	9.7	271
99	FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts. FEBS Letters, 2004, 564, 14-18.	2.8	68
100	Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors. Science, 2004, 306, 1506-1507.	12.6	384
101	Scanning electron microscopy of cells and tissues under fully hydrated conditions. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3346-3351.	7.1	221
102	Autoinhibition Control. Science, 2003, 300, 750-752.	12.6	112
103	SH2 and PTB Domains in Tyrosine Kinase Signaling. Science Signaling, 2003, 2003, RE12.	3.6	228
104	A putative molecular-activation switch in the transmembrane domain of erbB2. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15937-15940.	7.1	247
105	FRS2Î± attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6684-6689.	7.1	160
106	Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor. Cell, 2002, 110, 669-672.	28.9	906
107	All Signaling Is Local?. Molecular Cell, 2002, 10, 218-219.	9.7	16
108	The Docking Protein FRS2Î± Controls a MAP Kinase-Mediated Negative Feedback Mechanism for Signaling by FGF Receptors. Molecular Cell, 2002, 10, 709-719.	9.7	142

#	Article	IF	Citations
109	A solid base for assaying protein kinase activity. Nature Biotechnology, 2002, 20, 232-233.	17.5	22
110	A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nature Genetics, 2002, 32, 411-414.	21.4	132
111	Solution structure of Grb2 reveals extensive flexibility necessary for target recognition. Journal of Molecular Biology, 2001, 306, 527-537.	4.2	59
112	Variations of Proline-Rich Kinase Pyk2 Expression Correlate with Prostate Cancer Progression. Laboratory Investigation, 2001, 81, 51-59.	3.7	49
113	Src and Pyk2 Mediate G-protein-coupled Receptor Activation of Epidermal Growth Factor Receptor (EGFR) but Are Not Required for Coupling to the Mitogen-activated Protein (MAP) Kinase Signaling Cascade. Journal of Biological Chemistry, 2001, 276, 20130-20135.	3.4	187
114	Novel fluorescent approaches for studying cell signaling in single cells. Nature Biotechnology, 2000, 18, 262-263.	17.5	7
115	Absence of marginal zone B cells in Pyk-2â€“deficient mice defines their role in the humoral response. Nature Immunology, 2000, 1, 31-36.	14.5	476
116	A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling. Molecular and Cellular Biology, 2000, 20, 1448-1459.	2.3	334
117	Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization. Molecular Cell, 2000, 6, 743-750.	9.7	1,024
118	The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development. Cell, 2000, 102, 211-220.	28.9	288
119	Cell Signaling by Receptor Tyrosine Kinases. Cell, 2000, 103, 211-225.	28.9	3,724
120	New Roles for Src Kinases in Control of Cell Survival and Angiogenesis. Cell, 2000, 100, 293-296.	28.9	274
121	Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity. Cell, 2000, 101, 413-424.	28.9	370
122	Stoichiometry, Kinetic and Binding Analysis of the Interaction between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor. Growth Factors, 2000, 18, 11-29.	1.7	67
123	Solution Structure of the SH2 Domain of Grb2/Ash Complexed with EGF Receptor-Derived Phosphotyrosine-Containing Peptide. Journal of Biochemistry, 1999, 125, 1151-1159.	1.7	6
124	The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. Oncogene, 1999, 18, 2908-2912.	5.9	24
125	Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-Î³, but not IFN-Î±, signaling. EMBO Journal, 1999, 18, 2480-2488.	7.8	131
126	Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. Oncogene, 1999, 18, 4647-4653.	5.9	25

#	Article	IF	Citations
127	Structural Basis for FGF Receptor Dimerization and Activation. Cell, 1999, 98, 641-650.	28.9	575
128	Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide. Journal of Molecular Biology, 1999, 289, 439-445.	4.2	63
129	Identification of a Novel Family of Targets of PYK2 Related to Drosophila Retinal Degeneration B (rdgB) Protein. Molecular and Cellular Biology, 1999, 19, 2278-2288.	2.3	133
130	Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature, 1998, 393, 812-817.	27.8	354
131	Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways. Oncogene, 1998, 16, 2425-2434.	5.9	18
132	Multi-ligand interactions with receptor-like protein tyrosine phosphatase Î²: implications for intercellular signaling. Trends in Biochemical Sciences, 1998, 23, 121-124.	7.5	96
133	Cell-contact-dependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase Î². Current Opinion in Neurobiology, 1998, 8, 117-127.	4.2	121
134	Switching Signals On or Off by Receptor Dimerization. Cell, 1998, 94, 277-280.	28.9	401
135	Autoregulatory Mechanisms in Protein-tyrosine Kinases. Journal of Biological Chemistry, 1998, 273, 11987-11990.	3.4	262
136	Disulfide Bond Structure of Human Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 1998, 273, 11150-11157.	3.4	77
137	Identification of a New Pyk2 Isoform Implicated in Chemokine and Antigen Receptor Signaling. Journal of Biological Chemistry, 1998, 273, 14301-14308.	3.4	121
138	Signal Transduction Due to HIV-1 Envelope Interactions with Chemokine Receptors CXCR4 or CCR5. Journal of Experimental Medicine, 1997, 186, 1793-1798.	8.5	383
139	Kit Receptor Dimerization Is Driven by Bivalent Binding of Stem Cell Factor. Journal of Biological Chemistry, 1997, 272, 6311-6317.	3.4	98
140	Induction of Neurite Outgrowth through Contactin and Nr-CAM by Extracellular Regions of Glial Receptor Tyrosine Phosphatase Î². Journal of Cell Biology, 1997, 136, 907-918.	5.2	168
141	Tyrosine Phosphorylation of Pyk2 Is Selectively Regulated by Fyn During TCR Signaling. Journal of Experimental Medicine, 1997, 185, 1253-1260.	8.5	158
142	Ligand-Binding Enhances the Affinity of Dimerization of the Extracellular Domain of the Epidermal Growth Factor Receptor. Journal of Biochemistry, 1997, 122, 116-121.	1.7	55
143	Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science, 1997, 276, 955-960.	12.6	1,047
144	Direct Binding and Activation of Receptor Tyrosine Kinases by Collagen. Cell, 1997, 91, 869-872.	28.9	83

#	Article	IF	Citations
145	Close Similarity between Drosophila Neurexin IV and Mammalian Caspr Protein Suggests a Conserved Mechanism for Cellular Interactions. Cell, 1997, 88, 745-746.	28.9	38
146	Conformation of an Shc-derived phosphotyrosine-containing peptide complexed with the Grb2 SH2 domain. Journal of Biomolecular NMR, 1997, 10, 273-278.	2.8	19
147	Identification of the Binding Site for Acidic Phospholipids on the PH Domain of Dynamin: Implications for Stimulation of GTPase Activity. Journal of Molecular Biology, 1996, 255, 14-21.	4.2	251
148	Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism. Cell, 1996, 86, 577-587.	28.9	378
149	PH Domains: Diverse Sequences with a Common Fold Recruit Signaling Molecules to the Cell Surface. Cell, 1996, 85, 621-624.	28.9	473
150	A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature, 1996, 383, 547-550.	27.8	956
151	Identification of a Novel 135-kDa Grb2-binding Protein in Osteoclasts. Journal of Biological Chemistry, 1996, 271, 33141-33147.	3.4	9
152	Thermodynamic Studies of SHC Phosphotyrosine Interaction Domain Recognition of the NPXpY Motif. Journal of Biological Chemistry, 1996, 271, 4770-4775.	3.4	33
153	Induction of Urokinase-type Plasminogen Activator by Fibroblast Growth Factor (FGF)-2 Is Dependent on Expression of FGF Receptors and Does Not Require Activation of Phospholipase Cî³1. Journal of Biological Chemistry, 1996, 271, 31154-31159.	3.4	21
154	[36] Use of tyrosine-phosphorylated proteins to screen bacterial expression libraries for SH2 domains. Methods in Enzymology, 1995, 255, 360-369.	1.0	5
155	Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature, 1995, 373, 536-539.	27.8	932
156	Scratching the surface with the PH domain. Nature Structural and Molecular Biology, 1995, 2, 715-718.	8.2	59
157	Use of Large Combinatorial Chemical Libraries for Anticancer Drug Discovery. International Journal of Pharmacognosy, 1995, 33, 67-74.	0.2	4
158	Reduced Activation of RAF-1 and MAP Kinase by a Fibroblast Growth Factor Receptor Mutant Deficient in Stimulation of Phosphatidylinositol Hydrolysis. Journal of Biological Chemistry, 1995, 270, 5065-5072.	3.4	94
159	Tyrosine Phosphorylation of the c-cbl Proto-oncogene Protein Product and Association with Epidermal Growth Factor (EGF) Receptor upon EGF Stimulation. Journal of Biological Chemistry, 1995, 270, 20242-20245.	3.4	182
160	Shc Binding to Nerve Growth Factor Receptor Is Mediated by the Phosphotyrosine Interaction Domain. Journal of Biological Chemistry, 1995, 270, 15125-15129.	3.4	122
161	Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?. Cell, 1995, 83, 357-360.	28.9	484
162	Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. Cell, 1995, 83, 1037-1046.	28.9	613

#	Article	IF	Citations
163	The carbonic anhydrase domain of receptor tyrosine phosphatase Î² is a functional ligand for the axonal cell recognition molecule contactin. Cell, 1995, 82, 251-260.	28.9	397
164	Definition of Signals for Neuronal Differentiation. Annals of the New York Academy of Sciences, 1995, 766, 1-17.	3.8	14
165	One Bead, One Chemical Compound: Use of the Selectide Process for Anticancer Drug Discovery. Acta OncolÃ³gica, 1994, 33, 127-131.	1.8	8
166	Regulation of signal transduction and signal diversity by receptor oligomerization. Trends in Biochemical Sciences, 1994, 19, 459-463.	7.5	438
167	Structure of the N-terminal SH3 domain of GRB2 complexed with a peptide from the guanine nucleotide releasing factor Sos. Nature Structural and Molecular Biology, 1994, 1, 891-897.	8.2	103
168	Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. Structure, 1994, 2, 423-438.	3.3	239
169	Solution structure and ligandâ€“binding site of the carboxyâ€“terminal SH3 domain of GRB2. Structure, 1994, 2, 1029-1040.	3.3	74
170	PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation. Current Biology, 1994, 4, 702-708.	3.9	216
171	Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell, 1994, 78, 949-961.	28.9	469
172	SH2/SH3 signaling proteins. Current Opinion in Genetics and Development, 1994, 4, 25-30.	3.3	432
173	Vav: A potential link between tyrosine kinases andRas-like GTPases in hematopoietic cell signaling. BioEssays, 1993, 15, 179-183.	2.5	22
174	Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature, 1993, 363, 88-92.	27.8	580
175	Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature, 1993, 366, 583-585.	27.8	363
176	Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/SH2 domain binding. Biochemistry, 1993, 32, 3197-3202.	2.5	165
177	How receptor tyrosine kinases activate ras. Trends in Biochemical Sciences, 1993, 18, 273-275.	7.5	367
178	Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell, 1993, 73, 541-554.	28.9	277
179	The expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system. Developmental Brain Research, 1993, 75, 293-298.	1.7	92
180	Characterization of the submicroscopic deletion in the small-cell lung carcinoma (SCLC) cell line U2020. Genes Chromosomes and Cancer, 1992, 5, 67-74.	2.8	26

#	Article	IF	Citations
181	PDGF stimulation of inositol phospholipid hydrolysis requires PLC-Î³1 phosphorylation on tyrosine residues 783 and 1254. Cell, 1991, 65, 435-441.	28.9	570
182	Cloning, Expression of the Human Substance K Receptor, and Analysis of Its Role in Mitogenesis. Annals of the New York Academy of Sciences, 1991, 632, 426-427.	3.8	2
183	Mitogenic Effects of Fibroblast Growth Factors in Cultured Fibroblastsa.. Annals of the New York Academy of Sciences, 1991, 638, 161-166.	3.8	45
184	Interaction of Epidermal Growth Factor with Vasoactive Hormones in the Regulation of Phospholipase A2. Journal of Basic and Clinical Physiology and Pharmacology, 1991, 2, 161-182.	1.3	7
185	Signal transduction by receptors with tyrosine kinase activity. Cell, 1990, 61, 203-212.	28.9	5,482
186	Anti-Epidermal Growth Factor Receptor Antibodies Inhibit the Autocrine-Stimulated Growth of MDA-468 Human Breast Cancer Cells. Molecular Endocrinology, 1989, 3, 1830-1838.	3.7	138
187	Signal transduction by EGF-receptor and ist mutants. Cell Differentiation and Development, 1989, 27, 114.	0.4	0
188	Characterization of receptors for bombesin/gastrin-releasing peptide in human and murine cells. Methods in Enzymology, 1989, 168, 481-493.	1.0	15
189	Identification of the Bombesin Receptor on Murine and Human Cells by Cross-Linking Experiments. Annals of the New York Academy of Sciences, 1988, 547, 474-476.	3.8	0
190	Signal transduction by allosteric receptor oligomerization. Trends in Biochemical Sciences, 1988, 13, 443-447.	7.5	386
191	Onset of endogenous synthesis of epidermal growth factor in neonatal mice. Developmental Biology, 1987, 119, 38-44.	2.0	110
192	Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell, 1987, 51, 1063-1070.	28.9	647
193	Subcellular distribution of the external and internal domains of the EGF receptor in A-431 cells. Experimental Cell Research, 1986, 166, 312-326.	2.6	33
194	A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor. Nature, 1986, 324, 68-70.	27.8	170
195	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature, 1985, 313, 144-147.	27.8	1,464
196	The Drosophila EGF receptor gene homolog: Conservation of both hormone binding and kinase domains. Cell, 1985, 40, 599-607.	28.9	213
197	Monoclonal antibodies associated with sodium channel block nerve impulse and stain nodes of Ranvier. Brain Research, 1984, 310, 168-173.	2.2	36
198	The dynamic interrelationships of actin and vinculin in cultured cells. Cell Motility, 1983, 3, 399-403.	1.8	13

#	Article	IF	Citations
199	Regulation of Cell Proliferation by Epidermal Growth Factor. Critical Reviews in Biochemistry, 1983, 14, 93-111.	7.5	227
200	Mobilities of cell-membrane proteins: how are they modulated by the cytoskeleton?. Trends in Neurosciences, 1983, 6, 360-363.	8.6	6
201	5. Fluorescence Methods for Studying Membrane Dynamics. Methods in Experimental Physics, 1982, 20, 197-227.	0.1	8
202	Mobility of microinjected rhodamine actin within living chicken gizzard cells determined by fluorescence photobleaching recovery. Cell, 1982, 29, 835-845.	28.9	201
203	A non-mitogenic analogue of epidermal growth factor enhances the phosphorylation of endogenous membrane proteins. Biochemical and Biophysical Research Communications, 1981, 101, 517-523.	2.1	62
204	DYNAMICS OF HORMONE RECEPTORS ON CELL MEMBRANE. Annals of the New York Academy of Sciences, 1981, 366, 274-284.	3.8	7
205	Insulin and antibodies against insulin receptor cap on the membrane of cultured human lymphocytes. Nature, 1980, 286, 729-731.	27.8	65
206	The mechanism and role of hormone-induced clustering of membrane receptors. Trends in Biochemical Sciences, 1980, 5, 210-214.	7.5	129
207	Local aggregation of hormoneâ€“receptor complexes is required for activation by epidermal growth factor. Nature, 1979, 278, 835-838.	27.8	293
208	Collection of insulin, EGF and Î±2-Macroglobulin in the same patches on the surface of cultured fibroblasts and common internalization. Cell, 1978, 14, 805-810.	28.9	382
209	Lateral motion and valence of Fc receptors on rat peritoneal mast cells. Nature, 1976, 264, 550-552.	27.8	143
210	Molecular basis of negative co-operativity in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. Journal of Molecular Biology, 1974, 82, 547-561.	4.2	93